title: Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.
abstract: Androgen-deprivation therapy (ADT) induces prostate cancer immunogenic modulation (IM) by reducing human tumor cell expression of anti-apoptotic genes thus facilitating increased sensitivity to immune-mediated lysis. Through its stimulation of IM, ADT has been shown to synergize with active immunotherapy thereby significantly improving overall survival in a mouse model of prostate cancer.
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Bethesda, MD, USA.
authors.forename: Anna R
authors.initials: AR
authors.lastname: Kwilas
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Bethesda, MD, USA.
authors.forename: Sofia R
authors.initials: SR
authors.lastname: Gameiro
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Bethesda, MD, USA.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Kim
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Bethesda, MD, USA.
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Malamas
authors.affiliation: Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Bethesda, MD, USA.
authors.forename: James W
authors.initials: JW
authors.lastname: Hodge
keywords: Androgen-deprivation therapy; cancer immunotherapy; enzalutamide; immunogenic modulation; therapeutic cancer vaccine